Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eutravac
- Development stage
- Phase 3
- Lead developer
- LG Chem
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Eutravac** is a fixed-dose pediatric combination vaccine developed by LG Life Sciences and subsequently LG Chem for active immunization against diphtheria, tetanus, pertussis, and hepatitis B. It contains diphtheria toxoid, tetanus toxoid, detoxified purified pertussis antigens, and purified hepatitis B surface antigen. A registered Phase III study evaluated its immunogenicity and safety in healthy infants receiving primary immunization at 2, 4, and 6 months of age. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01896739))
- Brand names
- EutravacEutravac Inj.
- Other names
- DTaP-HB combined vaccineDTaP-HepB vaccine
02
Targets
TT (Tetanus toxoid)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Eutravac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eutravac.